BXP — Beximco Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- £95.91m
- £160.00m
- BDT39.27bn
- 96
- 99
- 19
- 86
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | BAS | BAS | BAS | BAS | BAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 22,817 | 25,612 | 29,494 | 34,669 | 39,267 |
Cost of Revenue | |||||
Gross Profit | 10,620 | 11,899 | 13,924 | 15,814 | 17,313 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 17,750 | 20,002 | 22,843 | 27,768 | 32,050 |
Operating Profit | 5,066 | 5,609 | 6,651 | 6,901 | 7,216 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 3,946 | 4,653 | 6,378 | 6,687 | 6,069 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,040 | 3,544 | 5,166 | 4,999 | 4,524 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 3,033 | 3,515 | 5,128 | 5,123 | 4,614 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,033 | 3,515 | 5,128 | 5,123 | 4,614 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 6.8 | 7.94 | 11.5 | 11.6 | 10.3 |
Dividends per Share |